




RealRate

PHARMACEUTICAL 2023

Lumos Pharma INC
Rank 142 of 471

lumos
PHARMA



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Lumos Pharma INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lumos Pharma INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 101% points. The greatest weakness of Lumos Pharma INC is the variable Other Revenues, reducing the Economic Capital Ratio by 9.4% points.

The company's Economic Capital Ratio, given in the ranking table, is 324%, being 79% points above the market average of 245%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	72,009	Assets	72,292
Cost of Goods Sold	0	Liabilities	12,708
Intangible Assets	0	Expenses	33,550
Liabilities, Current	6,708	Revenues	1,523
Liabilities, Non-Current	6,000	Stockholders Equity	59,584
Other Assets	230	Net Income	-31,062
Other Compr. Net Income	-9.0	Comprehensive Net Income	-31,066
Other Expenses	-13	BaseVar	60,524
Other Liabilities	0	ECR before LimitedLiability	233%
Other Net Income	965	Economic Capital Ratio	324%
Other Revenues	1,523		
Property and Equipment	53		
Research and Development	17,857		
Selling, General and Administrative Expense	15,706		